spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:   Ascites  

 HSMN NewsFeed - 12 Feb 2024
AbbVie Completes Acquisition of ImmunoGen
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 23 Jun 2021
BD Announces Expanded 510(k) Clearance for At-Home System for Ascites
Devices FDA
 HSMN NewsFeed - 15 Aug 2019
Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2019
Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress(TM) (EASL)
Biopharmaceuticals
 HSMN NewsFeed - 17 Aug 2018
Eisai And Merck Announce FDA Approval Of LENVIMA(R) (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2018
Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with SyntArray, LLC
Biopharmaceuticals Personalized Medicine Licensing
 HSMN NewsFeed - 24 Oct 2017
Sequana Medical Announces Results of the MOSAIC Trial Data Presented at 2017 AASLD
Devices
 HSMN NewsFeed - 24 Apr 2017
SIR-Spheres(R) Y-90 Resin Microspheres Substantially Improves Quality of Survival in Primary Liver Cancer, New Study Against Standard Treatment Shows
Devices Oncology
 HSMN NewsFeed - 15 Mar 2017
Julie G. Anderson Joins BioVie as Independent Director and Investor
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Dec 2016
Sequana Medical Announces Sudden Passing of Founder, President & CEO; Ian Crosbie Appointed Chief Executive Officer
Devices Personnel
 HSMN NewsFeed - 14 Oct 2016
Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva(R) (Obeticholic Acid) for the Treatment of Primary Biliary Cholangitis in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Sep 2016
BioVie's Lead Compound BIV201 Receives FDA Orphan-Drug Designation for the Treatment of Ascites
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Oct 2015
Sequana Medical AG Raises CHF 9 million (USD 9.3M) in a Series C Extension
Devices Venture Capital
 HSMN NewsFeed - 16 Apr 2015
Sequana Medical signs collaboration agreement with Fresenius Medical Care for the marketing and distribution of the alfapump(R) system
Devices Distribution
 HSMN NewsFeed - 30 Oct 2012
Sequana Medical Receives CE-Mark Approval for the use of its alfapump(R) System in Cancer Patients With Malignant ascites
Devices Oncology Regulatory
 HSMN NewsFeed - 20 Apr 2012
Sequana Medical’s ALFApump(R) System Proves to Be a Safe and Efficacious Breakthrough Technology in Ascites Management
Devices
 HSMN NewsFeed - 1 Mar 2012
Sequana Medical's ALFApump(R) System Receives Reimbursement in Germany for Breakthrough Technology in Ascites Management
Devices Regulatory Reimbursement
 HSMN NewsFeed - 4 Nov 2011
The Medical University of Vienna and Vienna General Hospital Perform the First two Commercial Implants Worldwide of Sequana Medical's ALFApump(R) System
Devices
 HSMN NewsFeed - 13 Jul 2011
Sequana Medical Receives CE Mark Approval for the ALFApump System and Adds Key Executive to Team
Devices Personnel
 HSMN NewsFeed - 30 May 2011
NovaShunt Announces the Launch of its New Corporate Identity: Sequana Medical
Devices
 HSMN NewsFeed - 25 Apr 2011
First Patient Enrolled in Gore Early TIPS for Ascites Study at Indiana University Hospital
Devices
 HSMN NewsFeed - 8 Feb 2011
Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2011
Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab(R)
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 18 Oct 2010
U.S. Food and Drug Administration Approves BARACLUDE(R) (entecavir) as a Treatment for Chronic Hepatitis B Patients with Evidence of Decompensated Liver Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jun 2010
Salix Pharmaceuticals Announces NDA Submission For XIFAXAN550 For Treatment of Non-Constipation Irritable Bowel Syndrome
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 24 Mar 2010
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Feb 2010
NovaShunt Starts its Pivotal Clinical Study "PIONEER" to Demonstrate the Clinical Value of the AFS System
Devices
 HSMN NewsFeed - 26 May 2009
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Apr 2009
Salix Presents Highly Statistically Significant Results from the Phase III Pivotal Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE)
Biopharmaceuticals
 HSMN NewsFeed - 19 Nov 2007
The Aethlon Hemopurifier(R) Reverses Immune Suppression in Cancer
Devices Oncology
 HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 17 Jul 2007
Secondary Endpoints of Phase II/III Study Confirm Clear Benefits from Treatment With removab(R) for Patients with Malignant Ascites
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2006
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 May 2006
Cardinal Health Completes Acquisition of Denver Biomedical, a Manufacturer of Specialized Medical Devices
Devices Mergers & Acquisitions
 HSMN NewsFeed - 10 May 2006
Five years after approval, Gleevec underscores the promise of targeted therapy to provide sustained disease control
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
Ascites
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.